OBJECTIVES: To investigate whether mildly elevated thyroid stimulating hormone (TSH) (<10 mIU/L) is associated with height in children independently of the growth hormone-insulin-like growth factor 1 (GH-IGF-1) axis, and to assess sex differences. METHODS: This retrospective cross-sectional study included 2,447 children aged 2-10 years presenting for slow growth evaluation (2022-2024). Multivariable linear regression was used with adjustment for age, sex, and IGF-1 SDS; restricted cubic splines (RCS) were used to assess the dose-response relationship. Sex-stratified and sensitivity analyses were performed. RESULTS: Mildly elevated TSH was present in 96 (3.92 %) children. Overall, TSH was inversely associated with height SDS (β=-0.03, p<0.001) independently of IGF-1; RCS confirmed linearity. The association was significant in boys (β=-0.03, p=0.002) and borderline in girls. Boys with elevated TSH had lower height SDS (β=-0.18, p=0.025). Sensitivity analyses: the association persisted after excluding low IGF-1 (β=-0.02, p=0.004) but not in children with short stature (height SDS ≤-2). CONCLUSIONS: Mildly elevated TSH is independently associated with reduced height in children aged 2-10 years, independent of IGF-1. The association was significant in boys and borderline in girls, with no significant interaction. The absence of bone age and parental height data is a major limitation. These findings support growth monitoring rather than routine levothyroxine therapy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: